Here's Why Pfizer (PFE) Fell More Than Broader Market

Pfizer (PFE) closed at $25.24 in the latest trading session, marking a -1.71% move from the prior day. The stock fell short of the S&P 500, which registered a loss of 0.28% for the day. Elsewhere, the Dow lost 0.52%, while the tech-heavy Nasdaq lost 0.08%. Heading into today, shares of the drugmaker had gained 4.52% over the past month, outpacing the Medical sector's gain of 3.31% and the S&P 500's gain of 4.03%.Investors will be eagerly watching for the performance of Pfizer in its upcoming earnings disclosure. The company's earnings report is set to be unveiled on November 4, 2025. It is anticipated that the company will report an EPS of $0.71, marking a 33.02% fall compared to the same quarter of the previous year. Meanwhile, the Zacks Consensus Estimate for revenue is projecting net sales of $16.97 billion, down 4.13% from the year-ago period. Regarding the entire year, the Zacks Consensus Estimates forecast earnings of $3.09 per share and revenue of $63.53 billion, indicating changes of -0.64% and -0.16%, respectively, compared to the previous year. It is also important to note the recent changes to analyst estimates for Pfizer. Such recent modifications usually signify the changing landscape of near-term business trends. With this in mind, we can consider positive estimate revisions a sign of optimism about the business outlook. Our research reveals that these estimate alterations are directly linked with the stock price performance in the near future. To take advantage of this, we've established the Zacks Rank, an exclusive model that considers these estimated changes and delivers an operational rating system. The Zacks Rank system, spanning from #1 (Strong Buy) to #5 (Strong Sell), boasts an impressive track record of outperformance, audited externally, with #1 ranked stocks yielding an average annual return of +25% since 1988. Over the last 30 days, the Zacks Consensus EPS estimate has witnessed a 1.15% decrease. Pfizer is currently sporting a Zacks Rank of #3 (Hold). Investors should also note Pfizer's current valuation metrics, including its Forward P/E ratio of 8.32. For comparison, its industry has an average Forward P/E of 14.65, which means Pfizer is trading at a discount to the group. Also, we should mention that PFE has a PEG ratio of 0.84. The PEG ratio is akin to the commonly utilized P/E ratio, but this measure also incorporates the company's anticipated earnings growth rate. The average PEG ratio for the Large Cap Pharmaceuticals industry stood at 1.59 at the close of the market yesterday. The Large Cap Pharmaceuticals industry is part of the Medical sector. This group has a Zacks Industry Rank of 59, putting it in the top 24% of all 250+ industries. The Zacks Industry Rank assesses the strength of our separate industry groups by calculating the average Zacks Rank of the individual stocks contained within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1. Don't forget to use Zacks.com to keep track of all these stock-moving metrics, and others, in the upcoming trading sessions. Quantum Computing Stocks Set To SoarArtificial intelligence has already reshaped the investment landscape, and its convergence with quantum computing could lead to the most significant wealth-building opportunities of our time.Today, you have a chance to position your portfolio at the forefront of this technological revolution. In our urgent special report, Beyond AI: The Quantum Leap in Computing Power, you'll discover the little-known stocks we believe will win the quantum computing race and deliver massive gains to early investors.Access the Report Free Now >>Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Pfizer Inc. (PFE): Free Stock Analysis ReportThis article originally published on Zacks Investment Research (zacks.com).Zacks Investment ResearchWeiter zum vollständigen Artikel bei Zacks Weiter zum vollständigen Artikel bei Zacks